Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
about
Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley FeverPeramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza InfectionsThe role of carbohydrates in infection strategies of enteric pathogensReverse Genetics Approaches for the Development of Influenza VaccinesInfluenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological ActivityReplication-competent fluorescent-expressing influenza B virusCompetitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in FerretsThe contrasting phylodynamics of human influenza B viruses.Domestic pigs are susceptible to infection with influenza B viruses.Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epitheliumReplication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies.A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action.Post-influenza aspergillosis, do not underestimate influenza B.Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.Neurologic Complications of Influenza B Virus Infection in Adults, Romania.Antiviral Drug-Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016.A review of neuraminidase inhibitor susceptibility in influenza strains.The chemistry and biology of guanidine natural products.Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.Sialylation of N-glycans: mechanism, cellular compartmentalization and function.A 3D-RISM/RISM study of the oseltamivir binding efficiency with the wild-type and resistance-associated mutant forms of the viral influenza B neuraminidase.Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral.Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection.Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.Structural aberration in R282K genetic mutation and antiviral drug-resistant H7N9 bird flu.Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug.Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.Susceptibility of influenza viruses to hypothiocyanite and hypoiodite produced by lactoperoxidase in a cell-free systemThe continual threat of influenza virus infections at the human-animal interface: What is new from a one health perspective?Inhibition of sialidase activity as a therapeutic approach
P2860
Q21092271-3FB8262B-1588-4E49-BD66-E30E454370F8Q26749578-2B706DA1-DBF8-4DB2-ABD3-5BF5212B62FBQ26851237-AE534AF6-B7B8-4A90-9B34-0B5C7795BB02Q28076140-6700096B-CB7D-4553-A7C3-DAB451A1D6C1Q28079041-A7A5F794-DEBE-4F41-A95D-9EA7010BE52AQ28387786-87784CD6-F2B5-4BBF-840C-C910737C0DC1Q28553195-C8CBC215-4A51-45ED-9EB8-DFEF4AB9BE10Q35249640-FCB2925A-8AFB-4425-BA11-962A621968B4Q35488726-0DD08B44-0FFF-43A5-8C01-B93DCE589B71Q35640944-3406A178-C598-44E6-9E5D-29C621EEBA29Q36281137-D21D45B8-19AD-4DE2-887F-6C28253F6B73Q37598513-2EE61EBB-1E2E-4BBF-82B5-6967BDE7B633Q37671496-5275CCD5-E5B1-416C-AFCA-231AE75F78C7Q37713074-AFAA67CF-573D-485F-9E99-BF994707AE96Q37722249-3011DB47-F2F7-429F-A131-245E659A4435Q37722326-C103268A-2F4A-4FEE-9C45-40FBBA951C43Q38258646-B212BAE9-D2A1-41EF-9AA9-B7BC791BAAA8Q38675089-5554162D-2450-4EAD-9604-5176EBEB082BQ38868293-9BC063AA-4829-481A-93BF-EEBBBF6F0B35Q38963385-F9549C34-1923-41CB-8C6E-31F63A679E47Q39038778-DE2B01E5-DC7A-4517-AB26-8B3EB764EDA2Q39722037-66C02EC2-833B-4150-9B6D-73FB206DA9BEQ40051127-2ECA758E-E56A-4F40-B0EF-7D7B6F5A1A58Q40094068-2E0E82FC-EA37-4F28-8B03-1C5397033D74Q40147965-56232626-B9F7-49C7-BF06-43D24F58ECD6Q43135268-B0DB8C68-597F-43AB-8DEA-25C502E235FFQ45859986-FF507323-CD46-4B36-B478-1E8DE09187F1Q47555226-F346D3AB-27E6-45CE-9141-95B56BAE7D96Q56987224-65169161-0C40-406C-83FD-3830F314154CQ57093697-733A5471-F668-4234-9D75-6A252DF569B2Q57816160-40E32631-7F3F-4F59-AB7D-53394B521113
P2860
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@ast
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@en
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@nl
type
label
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@ast
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@en
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@nl
prefLabel
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@ast
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@en
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@nl
P2860
P3181
P1433
P1476
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance
@en
P2093
Andrew J. Burnham
Tatiana Baranovich
P2860
P304
P3181
P356
10.1016/J.ANTIVIRAL.2013.08.023
P407
P577
2013-11-01T00:00:00Z